南财智讯2月10日电，赛分科技公告，公司于2026年2月9日召开第二届董事会2026年第一次会议，审议 通过《关于使用部分暂时闲置募集资金进行现金管理的议案》；同意使用最高不超过1.00亿元的部分暂 时闲置募集资金进行现金管理；投资品种为安全性高、流动性好、有保本约定的现金管理产品（包括但 不限于通知存款、定期存款、结构性存款、大额存单、国债逆回购、收益凭证等）；使用期限自2026年 2月14日起至2027年2月13日，12个月内有效；资金在额度及期限范围内可滚动使用；不会影响募集资金 投资项目进度和公司正常生产经营。 ...

证券日报网讯2月3日，赛分科技在互动平台回答投资者提问时表示，公司在扬州建有占地41，405平方 米的大规模生产基地，拥有生物大分子层析介质产能24，760升，为下游药物大规模生产提供充足且安 全稳定的产能保证。为了进一步满足下游医药行业快速增长的分离纯化需求，公司正在建设扬州二期工 程，预计将在2026年底建成，建成后合计(连同扬州一期)实现年产224，760升生物大分子层析介质的产 能，将进一步提升公司生物大分子层析介质的规模化生产能力，为公司业务拓展建立坚实的基础。 ...

证券日报网讯2月3日，赛分科技在互动平台回答投资者提问时表示，公司是全球范围内少数同时具备分 析色谱及工业纯化的先进研发及规模化生产能力的企业之一，是国内竞争中的主要参与者。公司依托自 主可控的工艺平台、行业领先的技术实力与卓越的产品表现，与国内生物医药行业各细分领域的领军企 业建立了色谱填料长期合作关系。未来，伴随下游医药行业市场规模持续扩容、国产替代进程加速推 进，叠加公司海外业务的稳步拓展，公司的市场占有率将进一步提升。 ...

Investment Rating - The investment rating for the healthcare industry is "Positive" and maintained [14] Core Insights - The funding levels for Chinese innovative pharmaceutical companies are increasing, leading to a gradual improvement in the research and development (R&D) investment sentiment within the industry. This is expected to usher in a new cycle of prosperity for the innovative drug industry chain [5][12] - The trend of external business development (BD) is likely to benefit the domestic early-stage research industry significantly, as new business models allow early-stage projects to become tradable and monetizable assets, enhancing R&D investment returns [13] Summary by Sections Innovative Chain Development Review - Before 2020, multiple factors converged to initiate a significant rise in China's innovative drug sector, leading to the rapid development of the innovative chain, including CXO and life sciences services [10][30] - From 2020 to the first half of 2022, the global public health crisis accelerated capital inflow into the biopharmaceutical sector, resulting in high demand and a leap in the innovative chain segment, which also triggered a wave of IPOs and substantial supply-side expansion [10][39] - The second half of 2022 to 2024 saw a transition from a heated to a cooling phase, with a significant shift in supply-demand dynamics leading to industry internal competition and pressure on revenues and profit margins [10][54][57] Improvement in R&D Investment Sentiment - Starting from 2025, the R&D investment sentiment in China's innovative drug sector is expected to improve, with companies experiencing increased funding levels. The total amount raised through IPOs and additional offerings in 2025 is projected to reach 201.5 billion yuan, a 145% year-on-year increase [11][62] - The potential milestone payments from external BD are expected to reach 880.5 billion yuan in 2025, marking a 185.9% year-on-year increase, indicating a robust funding environment for innovative drug companies [11] Benefits to Early-stage Research Industry - The new external BD business model enhances the R&D investment return rates for Chinese innovative drug companies, thereby increasing their willingness to invest in R&D [11][13] - The early-stage research industry, including drug discovery CROs and clinical trial services, is expected to benefit significantly from the external BD trend, with leading companies in these segments poised for rapid growth [13]

赛分科技回复称，公司目前已具备自产微球的能力。公司掌握了不同基质(琼脂糖、聚合物、硅胶)微球 材料制备的技术，对微球粒径、孔径、机械强度等能够进行精确调控。公司可合成粒径在1.7～125μm 微球，粒径分布精准控制1.1-1.3之间，孔径覆盖6nm-400nm等不同规格。此外，公司针对不同应用领域 开发合成出不同机械强度的微球，提高了产品选择性，可满足色谱填料的生产需求。 格隆汇1月28日｜有投资者在互动平台向赛分科技提问：请问贵司在纯化工艺过程中所使用的微球材料 是公司自给自足的还是向外采购的？ ...

格隆汇1月28日丨赛分科技(688758.SH)在互动平台表示，公司目前已具备自产微球的能力。公司掌握了 不同基质（琼脂糖、聚合物、硅胶）微球材料制备的技术，对微球粒径、孔径、机械强度等能够进行精 确调控。公司可合成粒径在1.7～125μm微球，粒径分布精准控制1.1-1.3之间，孔径覆盖6nm-400nm等不 同规格。此外，公司针对不同应用领域开发合成出不同机械强度的微球，提高了产品选择性，可满足色 谱填料的生产需求。 ...

Group 1 - The core viewpoint of the news is that Sai Fen Technology has shown significant financial performance and trading activity, with a notable increase in revenue and net profit year-on-year [2][3] - On January 21, 2025, Sai Fen Technology's stock price increased by 1.95%, with a trading volume of 56.85 million yuan, and a net financing purchase of 1.42 million yuan [1] - As of January 21, 2025, the total margin balance of Sai Fen Technology was 56.16 million yuan, accounting for 0.97% of its market capitalization, indicating a high level of financing activity compared to the past year [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - For the period from January to September 2025, Sai Fen Technology achieved an operating income of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, up 71.07% year-on-year [2] - The company has distributed a total of 27.90 million yuan in dividends since its A-share listing [3]

Group 1 - The core viewpoint of the news is that Sai Fen Technology experienced a slight decline in stock price and had notable financing activities on January 19, with a net financing outflow of 248.09 million yuan [1] - On January 19, Sai Fen Technology's financing buy amounted to 870.19 million yuan, while the financing repayment was 1,118.28 million yuan, resulting in a total financing balance of 5,832.21 million yuan [1] - The company's financing balance of 5,831.82 million yuan accounts for 1.02% of its circulating market value [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - The company's main business revenue composition includes: industrial purification segment 33.10%, industrial purification fillers 32.65%, analytical chromatography segment 16.73%, analytical chromatography columns 13.31%, and other segments contributing smaller percentages [2] - As of September 30, 2025, Sai Fen Technology achieved an operating income of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, with a year-on-year increase of 71.07% [2] Group 3 - Since its A-share listing, Sai Fen Technology has distributed a total of 27.90 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders in Sai Fen Technology was 7,159, a decrease of 31.51% from the previous period, while the average circulating shares per person increased by 57.01% [2][3] - The Southern Science and Technology Innovation Board 3-Year Open Mixed Fund (506000) has exited the list of the top ten circulating shareholders of Sai Fen Technology [3]

Core Insights - The company, Saifen Technology, specializes in chromatography columns and packing materials used for the analysis and purification of biopharmaceuticals and small molecule drugs, which are essential throughout the drug development process [2] - Saifen Technology has over 5,000 cumulative customers globally, including clients from several EU member states, indicating a broad market presence [2] - The company's revenue from the EU region is relatively small, primarily generated through direct sales by its US subsidiary or through distributors [2]

Core Viewpoint - The major shareholders of Suzhou Saifen Technology Co., Ltd. plan to reduce their holdings in the company, with specific details on the number of shares and methods of reduction outlined in the announcement [2][3][4]. Shareholding Structure - Anhui Tonghua High-tech Center (Limited Partnership) holds 31,050,000 shares, accounting for 7.46% of the total share capital of the company [2]. - Nanjing Huatai Health One Equity Investment Partnership (Limited Partnership) holds 20,146,701 shares, accounting for 4.84% [2]. - Nanjing Huatai Health Two Equity Investment Partnership (Limited Partnership) holds 1,380,391 shares, accounting for 0.33% [2]. - Nanjing Daoxing Venture Capital Management Center (General Partnership) holds 322,909 shares, accounting for 0.08% [2]. - The total shares held by Huatai Health One, Huatai Health Two, and Daoxing Investment amount to 21,850,001 shares, representing 5.25% of the total share capital [2]. Reduction Plan - Tonghua High-tech plans to reduce its holdings by up to 12,493,923 shares, which is a maximum of 3% of the total share capital [3]. - The reduction will occur through centralized bidding and block trading, with a maximum of 4,164,641 shares (1% of total share capital) through centralized bidding and 8,329,282 shares (2% of total share capital) through block trading [3]. - The reduction period will begin 15 trading days after the announcement and will last for three months [3]. Shareholder Commitments - Tonghua High-tech and other shareholders have made commitments regarding their shareholding, including a lock-up period of 12 months post-IPO during which they will not transfer or manage their shares [5][6]. - They will adhere to relevant laws and regulations regarding share reduction and information disclosure [6][8]. - Any reduction in shares will be adjusted based on market conditions and corporate actions such as stock splits or capital increases [4][10]. Compliance and Governance - The reduction plan complies with the regulations set forth by the China Securities Regulatory Commission and the Shanghai Stock Exchange [11]. - The major shareholders have confirmed that there are no circumstances that would prevent them from reducing their shares [9][11].